Mazdutide activates glucagon and GLP-1 receptors and has phase III evidence in Chinese adults. Name the trial and assessment time when describing benefit.
What did GLORY-1 find?
The 2025 trial in 610 participants found greater weight reduction than placebo and improvements in selected cardiometabolic measurements. Gastrointestinal events were common, usually mild or moderate. Reference: Mazdutide GLORY-1 phase III trial (2025)
Is newer research available?
A 2026 GLORY-2 report studied Chinese adults with obesity using a different population and follow-up from GLORY-1. Its percentages should not be merged with the earlier trial into a single result. Reference: Mazdutide GLORY-2 trial (2026)
How should benefits be interpreted?
Consider daily function and adverse outcomes alongside weight. Weight-loss percentages alone do not identify how much was fat or how well muscle was preserved.
Frequently asked questions
Are Mazdutide and Semaglutide the same substance?
No. Match each compound to its own research.
Do group results guarantee individual outcomes?
No. Population, duration and care setting matter.
How should this article be used?
Use it to identify the substance, understand what the cited research measured, and prepare questions for a qualified clinician. It is educational information, not an individual treatment plan.